Folic acid supplementation before and during pregnancy in the Newborn Epigenetics STudy (NEST).

Hoyo, Cathrine; Murtha, Amy P; Schildkraut, Joellen M; Forman, Michele R; Calingaert, Brian; Demark-Wahnefried, Wendy; Kurtzberg, Joanne; Jirtle, Randy L; Murphy, Susan K

Folic acid supplementation before and during pregnancy in the Newborn Epigenetics STudy (NEST).

dc.contributor.author	Hoyo, Cathrine
dc.contributor.author	Murtha, Amy P
dc.contributor.author	Schildkraut, Joellen M
dc.contributor.author	Forman, Michele R
dc.contributor.author	Calingaert, Brian
dc.contributor.author	Demark-Wahnefried, Wendy
dc.contributor.author	Kurtzberg, Joanne
dc.contributor.author	Jirtle, Randy L
dc.contributor.author	Murphy, Susan K
dc.date.accessioned	2022-03-23T19:08:29Z
dc.date.available	2022-03-23T19:08:29Z
dc.date.issued	2011-01-21
dc.date.updated	2022-03-23T19:08:28Z
dc.description.abstract	Background Folic acid (FA) added to foods during fortification is 70-85% bioavailable compared to 50% of folate occurring naturally in foods. Thus, if FA supplements also are taken during pregnancy, both mother and fetus can be exposed to FA exceeding the Institute of Medicine's recommended tolerable upper limit (TUL) of 1,000 micrograms per day (μg/d) for adult pregnant women. The primary objective is to estimate the proportion of women taking folic acid (FA) doses exceeding the TUL before and during pregnancy, and to identify correlates of high FA use. Methods During 2005-2008, pre-pregnancy and pregnancy-related data on dietary supplementation were obtained by interviewing 539 pregnant women enrolled at two obstetrics-care facilities in Durham County, North Carolina. Results Before pregnancy, 51% of women reported FA supplementation and 66% reported this supplementation during pregnancy. Before pregnancy, 11.9% (95% CI = 9.2%-14.6%) of women reported supplementation with FA doses above the TUL of 1,000 μg/day, and a similar proportion reported this intake prenatally. Before pregnancy, Caucasian women were more likely to take FA doses above the TUL (OR = 2.99; 95% = 1.28-7.00), compared to African American women, while women with chronic conditions were less likely to take FA doses above the TUL (OR = 0.48; 95%CI = 0.21-0.97). Compared to African American women, Caucasian women were also more likely to report FA intake in doses exceeding the TUL during pregnancy (OR = 5.09; 95%CI = 2.07-12.49). Conclusions Fifty-one percent of women reported some FA intake before and 66% during pregnancy, respectively, and more than one in ten women took FA supplements in doses that exceeded the TUL. Caucasian women were more likely to report high FA intake. A study is ongoing to identify possible genetic and non-genotoxic effects of these high doses.
dc.identifier	1471-2458-11-46
dc.identifier.issn	1471-2458
dc.identifier.issn	1471-2458
dc.identifier.uri	https://hdl.handle.net/10161/24636
dc.language	eng
dc.publisher	Springer Science and Business Media LLC
dc.relation.ispartof	BMC public health
dc.relation.isversionof	10.1186/1471-2458-11-46
dc.subject	Humans
dc.subject	Pregnancy Complications
dc.subject	Chronic Disease
dc.subject	Folic Acid
dc.subject	Body Size
dc.subject	Prenatal Care
dc.subject	Prospective Studies
dc.subject	Health Knowledge, Attitudes, Practice
dc.subject	Smoking
dc.subject	Marital Status
dc.subject	Epigenesis, Genetic
dc.subject	Gestational Age
dc.subject	Pregnancy
dc.subject	Socioeconomic Factors
dc.subject	Dietary Supplements
dc.subject	Adult
dc.subject	Infant, Newborn
dc.subject	African Americans
dc.subject	Asian Americans
dc.subject	European Continental Ancestry Group
dc.subject	Hispanic Americans
dc.subject	North Carolina
dc.subject	Female
dc.subject	Surveys and Questionnaires
dc.subject	Catchment Area, Health
dc.title	Folic acid supplementation before and during pregnancy in the Newborn Epigenetics STudy (NEST).
dc.type	Journal article
duke.contributor.orcid	Kurtzberg, Joanne\|0000-0002-3370-0703
duke.contributor.orcid	Murphy, Susan K\|0000-0001-8298-7272
pubs.begin-page	46
pubs.issue	1
pubs.organisational-group	Duke
pubs.organisational-group	Nicholas School of the Environment
pubs.organisational-group	School of Medicine
pubs.organisational-group	Faculty
pubs.organisational-group	Clinical Science Departments
pubs.organisational-group	Institutes and Centers
pubs.organisational-group	Family Medicine and Community Health
pubs.organisational-group	Pathology
pubs.organisational-group	Pediatrics
pubs.organisational-group	Family Medicine and Community Health, Prevention Research
pubs.organisational-group	Duke Cancer Institute
pubs.organisational-group	Environmental Sciences and Policy
pubs.organisational-group	Institutes and Provost's Academic Units
pubs.organisational-group	Initiatives
pubs.organisational-group	Duke Innovation & Entrepreneurship
pubs.organisational-group	Pediatrics, Transplant and Cellular Therapy
pubs.publication-status	Published
pubs.volume	11